Press Releases

Date	Title	PDF Version
Jan 30, 2020	Alexion Reports Fourth Quarter and Full Year 2019 Results
Jan 28, 2020	Alexion Completes Acquisition of Achillion
Jan 24, 2020	UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020
Jan 17, 2020	Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020
Jan 14, 2020	Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS
Jan 06, 2020	Alexion to Present at the 38th Annual J.P Morgan Healthcare Conference
Dec 16, 2019	Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™
Dec 06, 2019	Alexion Issues Statement on Path to Value Creation
Nov 26, 2019	Alexion to Present at the 2019 Evercore ISI HealthCONx
Nov 22, 2019	SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Search